Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda's LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV)

11/24/2021 | 07:22am EST

OSAKA, Japan, and CAMBRIDGE, Mass. - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ('Takeda') announced that the U.S. Food and Drug Administration (FDA) has approved LIVTENCITY (maribavir) for the treatment of adults and pediatric patients (12 years of age or older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet.1 Overall, more than twice the proportion of adult transplant patients with refractory or resistant (R/R) CMV infection/disease achieved confirmed CMV DNA level

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
02:13pTAKEDA PHARMACEUTICAL : to Hold Third Quarter FY2021 Earnings Conference Call
PU
01/19Takeda Named Global Top Employer for Fifth Consecutive Year
BU
01/13Denali Therapeutics Shares Fall as FDA Puts Alzheimer's Study Plan on Hold
DJ
01/13Takeda Pharmaceutical Buys Back $434 Million of Shares as Part of Buyback Program Set t..
MT
01/12Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40..
AQ
01/12S.Korea authorises Novavax COVID-19 vaccine, imports Pfizer pills
RE
01/11S.Korea authorizes Novavax COVID-19 vaccine, imports Pfizer pills
RE
01/11Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta T Cell Engager ..
AQ
01/11Takeda Pharmaceutical Says Its Global Brands Are Expected to Hit Revenue Growth Target
MT
01/10PRESENTATION : Better health for people, Brighter future for the world
PU
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 411 B 29 996 M 29 996 M
Net income 2022 208 B 1 831 M 1 831 M
Net Debt 2022 3 307 B 29 081 M 29 081 M
P/E ratio 2022 24,4x
Yield 2022 5,42%
Capitalization 5 176 B 45 488 M 45 521 M
EV / Sales 2022 2,49x
EV / Sales 2023 2,38x
Nbr of Employees 47 099
Free-Float 98,2%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 323,00 JPY
Average target price 3 951,43 JPY
Spread / Average Target 18,9%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED5.99%45 419
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833